BioSig announces public offering of common stock to fund gold purchases

NEW YORK - BioSig Technologies, Inc. (NASDAQ:BSGM), which recently merged with Streamex Exchange Corporation and has seen its stock surge over 798% in the past year, announced Wednesday its plans to conduct an underwritten public offering of common stock or pre-funded warrants.

The company, which maintains a healthy balance sheet with a current ratio of 2.37 and minimal debt, intends to use the net proceeds to purchase gold bullion in accordance with its investment policy, as well as for working capital and general corporate purposes, according to a press release statement.

Clear Street and Needham & Company will serve as joint book-running managers for the offering, which is being made pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission.

The timing, size, and terms of the offering remain subject to market conditions, with no assurance of completion.

BioSig Technologies operates in two distinct business areas following its merger with Streamex. The company, currently valued at approximately $80 million, maintains its medical device technology division, which develops the PURE EP Platform for electrophysiologists performing cardiac arrhythmia ablation treatments. Through its Streamex subsidiary, BioSig is also developing infrastructure for gold tokenization and bringing gold markets onto blockchain technology. InvestingPro analysis reveals 12+ additional key insights about BSGM’s financial health and market position.

A preliminary prospectus supplement related to the offering will be filed with the SEC. The company stated that the securities will not be sold in any state where such offer would be unlawful prior to registration or qualification under securities laws.

In other recent news, BioSig Technologies, Inc. announced definitive agreements for up to $1.1 billion in growth financing. This package includes $100 million in senior secured convertible debentures and a $1 billion equity line of credit, positioning BioSig to become one of Nasdaq’s largest public holders of gold bullion following its merger with Streamex Exchange Corporation. Additionally, BioSig has amended its debenture agreement with Yorkville, allowing for secured convertible debentures totaling up to $100 million. The amendment includes modifications to purchase, closing, and stockholder approval provisions.

BioSig’s subsidiary, Streamex Exchange Corporation, is also making moves by engaging Compliance Exchange Group to manage the acquisition of a FINRA and SEC registered broker-dealer. This acquisition aims to position Streamex as a leader in issuing regulated Real-World Asset tokens in the U.S., focusing on gold-backed digital assets. Furthermore, BioSig has appointed Russell Starr as a Strategic Advisor to Streamex, bringing experience in capital markets and decentralized finance. Trevor Bacon and Kellan Grenier, co-founders of Parcl, have also joined as Strategic Advisors to advance BioSig’s commodity market initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.